Sub head

From the outset, ACU193 was designed to selectivity target the toxic oligomers to provide Alzheimer’s patients with meaningful clinical benefits with an attractive safety profile. ACU193 has demonstrated safety and efficacy in biomarkers and cognitive behavior in multiple pre-clinical in-vitro and in-vivo Alzheimer’s models.   Our lead candidate ACU193 was designed to selectivity target toxic amyloid-beta oligomers  to provide Alzheimer’s patients with meaningful clinical benefits with an attractive safety profile.

ACU193 has demonstrated safety and efficacy in biomarkers and cognitive behavior in multiple pre-clinical in-vitro and in-vivo Alzheimer’s models. We have has commenced CMC and pre-clinical activities and expect to obtain IND approval and initiate clinical trials for ACU193 in 2020.